Primary Care Diabetes
Volume 2, Issue 1 , Pages 9-16 , 2008

Initiating insulin in primary care—The role of modern premixed formulations

  • Robert Ligthelm

      Affiliations

    • EHM Clinic Hoofddorp, 's-Gravenweg 53, Rotterdam 3062 ZB, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 10 4135477; fax: +31 10 4135477.
    • ,
  • Jaime Davidson

      Affiliations

    • University of Texas Southwestern Medical School, Dallas, Texas, USA

Received 8 October 2007 ,Revised 11 December 2007 ,Accepted 8 January 2008.

References 

  1. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  2. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr. Med. Res. Opin. 2003;19:635–641
  3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 1995;28:103–117
  4. Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabetes Med. 2005;22:1379–1385
  5. Peyrot M, Rubin R, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679
  6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord. 2002;26(Suppl. 3):S18–S24
  7. Rizvi A, Ligthelm R. The use of premixed insulin analogues in the treatment of type 2 diabetes: advantages and limitations. Insulin. 2007;2:68–79
  8. Walley T, Hughes D, Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992–2003. Pharmacoepidemiol. Drug Saf. 2005;14:769–773
  9. Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?. Diabetes Care. 2005;28:600–606
  10. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA. 1989;262:907–913Erratum in: JAMA 262 (18) (1989) 2542
  11. Greenfield S, Nelson EC, Zubkoff M, et al. Variations in resource utilization among medical specialties and systems of care. Results from the Medical Outcomes Study. JAMA. 1992;267:1624–1630
  12. Greenfield S, Rogers W, Mangotich M, et al. Outcomes of patients with hypertension and noninsulin-dependent diabetes mellitus treated by different systems and specialties: results from the Medical Outcomes Study. JAMA. 1995;274:1436–1444
  13. O’Connor PJ, Solberg LI, Baird M. The future of primary care. The enhanced primary care model. J. Fam. Pract. 1998;47:62–67
  14. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness?. Eff. Clin. Pract. 1998;1:2–4
  15. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–1779
  16. National Coalition on Health Care, Institute for Health Improvement, Curing the system, www.improvingchroniccare.org/ACT_Report_May_2002_Curing_The_System.pdf.
  17. Supporting people with long-term conditions: An NHS and Social Care Model to support local innovation and integration, UK Department of Health, 2005 http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&dID=4384&Rendition=Web.
  18. Health and Social Care Information Centre, Quality and Outcomes Framework, 2004/05, HSCIC, London, available at http://www.ic.nhs.uk/services/qof/data, 2005.
  19. J.N. Struijs, G.P. Westert, C.A. Baan, Effect evaluation of transmural diabetes care in the Netherlands, http://www.rivm.nl/bibliotheek/rapporten/260402001.html.
  20. Dromgoole P. How workshops can support health staff helping patients move to insulin therapy. Prof. Nurse. 2004;19:26–28
  21. Fitzsimons B, Wilton L, Lamont T, et al. The Audit Commission review of diabetes services in England and Wales, 1998–2001. Diabetes Med. 2002;19:73–78
  22. Farooqi A, Dodd L, Stribling B, et al. Diabetes Service Provision in Primary Care: a baseline survey in a city Primary Care Trust (PCT). Pract. Diabetes Int. 2004;21:13–17
  23. Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. JAMA. 2002;288:475–482
  24. Goudswaard AN, Stolk RP, Zuithoff P, Rutten GEHM. Patient characteristics do not predict poor glycaemic control in type 2 diabetes patients treated in primary care. Eur. J. Epidemiol. 2004;19:541–545
  25. Peyrot M, Rubin RR, Lauritzen T, et al. Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study. Diabetologia. 2006;49:279–288
  26. Skyler JS. Insulin therapy in type II diabetes: who needs it, how much of it, and for how long?. Postgrad. Med. 1997;101:85–9092–94, 96
  27. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30:263–269
  28. The DECODE Study Group, On behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 2001;161:397–405
  29. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur. J. Clin. Pharmacol. 2000;56:399–403
  30. Radziuk JR, Bradley B, Welsh L, et al. Neutral protamine lispro: activity profile of s.c. administration with and without admixture of soluble lispro. Diabetologia. 1996;39(Suppl. 1):A224;(Abstract)
  31. Janssen MMJ, Casteleijn S, Deville W, et al. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care. 1997;20:1870–1873
  32. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res. Clin. Pract. 1999;43:137–142
  33. The Lispro Mixture-Glargine Study Group. Combined therapy with insulin Lispro Mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin. Ther. 2004;26:2034–2044
  34. The INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  35. Holman RR, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 2007;357(17):1716–1730
  36. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care. 2003;26:881–885
  37. Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J. Diabetes Complications. 2006;20:145–152
  38. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin. Ther. 2002;24:530–539
  39. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabetes Med. 2002;19:393–399
  40. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Diabetes Care. 1997;20:1612–1614
  41. Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25:883–888
  42. Davidson J, Liebl A, Christiansen JS, et al. Biphasic insulin aspart is associated with a reduced risk of hypoglycaemia compared with biphasic human insulin. Diabetologia. 2007;50(Suppl. 1):S408
  43. IDF Clinical Guidelines Task Force, Global guideline for type 2 diabetes, International Diabetes Federation, Brussels, 2005.
  44. Rakel RE. The role of the family physician in the diagnosis and treatment of type 2 diabetes mellitus. J. Fam. Pract. 2006;(December (Suppl.)):5–9
  45. Shaefer CF. Clinical inertia: overcoming a major barrier to diabetes management. Insulin. 2006;1:61–64
  46. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract. 2007;13(Suppl. 1):1–68
  47. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care. 2003;26:3273–3279
  48. NovoMix dosing guidelines, http://www.novonordisk.com/images/diabetes/pdf/novomix_dosing_guidelines_60317.pdf.
  49. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes Obes. Metab. 2006;8:58–66
  50. Ligthelm R. Biphasic Insulin Aspart 30 (BIAsp 30) in clinical reality: experience from a Dutch practice. Diabetes. 2007;56(Suppl. 1):A540
  51. Roach P, Yue L, Arora V Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care. 1999;22:1258–1261
  52. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?. Eur. J. Clin. Invest. 2000;30(Suppl. 2):3–11
  53. Del Prato S. Post-prandial hyperglycaemia: the necessity for better control. Int. J. Clin. Pract. 2000;112:3–8
  54. Ceriello A. The emerging role of postprandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetes Med. 1998;15:188–193
  55. The DECODE Study Group, European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617–621
  56. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin. Ther. 2007;29(6P):1254–1270
  57. Kapitza C, Rave K, Ostrowski K, et al. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabetes Med. 2004;21:500–501
  58. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin. Ther. 2005;27(Suppl. B):S89–S100
  59. White RD. Options for insulin delivery and overcoming physician and patient concerns. J. Fam. Pract. 2006;(December (Suppl.)):18–24
  60. Niskanen L, Jensen LE, Råstam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin. Ther. 2004;26:531–540
  61. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin. Ther. 2003;25:2836–2848
  62. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27:2495–2497
  63. Raskin P, Rojas P, Allen E. Comparison of twice-daily aspart 70/30 (BIAsp 70/30) with once-daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabetic agents. Diabetes. 2004;53(Suppl. 2):A143

PII: S1751-9918(08)00003-X

doi: 10.1016/j.pcd.2008.01.005

Primary Care Diabetes
Volume 2, Issue 1 , Pages 9-16 , 2008

Article Tools

* Image Usage & Resolution